The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
AACR 2021 | Future treatment of relapsed iNHL
Matthew Matasar, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, discusses the future treatment of indolent non-Hodgkin lymphoma (iNHL), highlighting the use of copanlisib and rituximab in combination. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.
Disclosures
Matthew Matasar, MD, has received support and honoraria from Bayer and Roche.
